WHY: Making the world disease free.



HOW: We find the real drug lead candidate by capturing the synergistic effect of mutations (epistasis).



WHAT: We have developed the Data-Centric innov’SAR AI industrial platform for our partners.



PEACCEL is definitely the ONLY company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of "hit rate".

We can solve the "1+1=10" challenge!



The innov'SAR core approach is interpolative, extrapolative and predicts outside-of-the-box, not found in other state-of-the-art ML / DL.

It can screen 1 billion mutants per day.



PEACCEL can produce massive amounts of Synthetic data to train its ML/DL platform.

Other companies have taken the shortcut of relying on existing datasets which are often messy and of low quality.



PEACCEL is built around the 6 pillars - P6 -:

PLATFORM, PUBLICATIONS, PATENTS, PARTNERSHIPS, PRODUCTS and PEOPLE



 We have developed the innov'SAR PLATFORM, including 4 modules :

1- innov’SAR core: For the optimization of polypeptides (peptides, proteins, enzymes, antibodies, VHHs)

2- RAS module: For evaluating combination of Drugs (FDCs) in various diseases

3- automlSAR: this tool tests in parallel >135 algorithms, is agnostic with respect to the data set and can be combined with innov’SAR core & RAS module

4- GraphMut: Graph-based visualization tool of relations between the mutations of protein sequence variants and activity variations



 15 PUBLICATIONS in the last 2 years



 Strong worldwide PATENTS (on technology using FFT), with more to come



 Robust PARTNERSHIPS with top notch KOLs worldwide



 Focus on high value PRODUCTS



 Highly skilled PEOPLE in high-tech fields.